Formycon AG (ETR:FYB)
Germany flag Germany · Delayed Price · Currency is EUR
15.48
+0.20 (1.31%)
Nov 16, 2026, 12:46 PM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

Nine-month revenue more than doubled and reported EBITDA improved, but FYB201/FYB202 impairments reflect tougher markets. FYB206’s FDA file acceptance and unchanged core guidance underpin the next growth phase.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Formycon AG earnings call, nine months of 2026. The conference will be recorded. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions following the presentation within the conference call. Let me now turn the floor over to your host, Dr. Stefan Glombitza.

Stefan Glombitza
CEO, Formycon

Yeah, thank you for the introduction. Good afternoon, good morning, and a warm welcome to everyone joining us today. With the publication of our nine-month results earlier today, we have reached another milestone in our financial year. Before we begin, please note that both our presentation and the subsequent Q&A contain forward-looking statements that are subject to the usual risks and uncertainties as outlined in our disclaimer. In today's call, we will focus, of course, on our nine-month results and provide additional context around the impairment announcement we made last week. We will explain what drove these adjustments, what they mean for our existing products, and importantly, how we are incorporating these market learnings into our strategy and the next generation of our portfolio. We will also highlight our operational progress and show how it reflects the meticulous execution of our FYB4Growth strategy.

Before we turn to the details of the presentation, let me start with a few key takeaways from the first nine months of 2026. First, our financial performance, and I will later on show more details on that, has improved substantially year on year. Our nine-month results are significantly ahead of the comparable period in 2025. At the same time, our business is not linear, and revenues are not evenly distributed across quarters. We saw this very clearly last year, and the fourth quarter made a particularly strong contribution to our full-year guidance. Looking ahead, we again expect a strong fourth quarter. On this basis, our 2026 guidance for our most relevant financial KPIs remains unchanged: revenue, EBITDA, and working capital. At the same time, the markets for our first two commercialized products have continued to change. Additional competitors coming in, increasing price pressure, and a shift to therapeutic alternatives.

These developments have affected the sales performance and the longer-term expectations of our commercial partners. As a consequence, we now expect our 2026 performance to come in towards the lower end of our guidance range for revenue and EBITDA, and the revised longer-term partner forecasts were also the basis for the book value adjustments we communicated last week. While this is clearly not a development we welcome, it is important to put it into perspective. The fundamental progress of our business and the quality of our development platform remain unchanged. We are applying the lessons from our first-generation products very deliberately to the next generation of our portfolio to ensure sustainable economic success. And this brings me to the operational progress we have made. On October 13, we became the first company worldwide to announce FDA file acceptance for FYB206, our biosimilar candidate to KEYTRUDA.

This represents an important milestone for Formycon and validates both the speed and the quality of our development capabilities. We also signed an agreement for FYB286, adding an additional attractive asset in the niche-buster category to our portfolio. With that, we have further strengthened our manufacturing network by adding another strategic partnership with Biocelys in South America, complementing the partnership with OneSource that we announced with our half-year results. Taken together, these are important steps in our FYB4Growth journey towards a more diversified, competitive, and over the long term, sustainably profitable business. Before looking at our recent achievements, I would like to put last week's impairment announcement into a broader strategic context. As communicated, we have recognized value adjustments for FYB201 and FYB202. Both products operate in markets that have changed considerably since we acquired the rights in 2022.

Let me be clear, however, these products will continue to generate revenues and cash flows for Formycon in the years ahead, based on the revised partner forecasts. We remain fully committed to driving the commercialization of our existing portfolio. It continues to be an important source of revenues and cash flows, supporting our business as we advance FYB206 and the next generation of biosimilars towards commercialization. There is another important perspective. FYB201 and FYB202 were among the products on which we built Formycon's development platform and established the track record you see on this slide. We have demonstrated several times that we can develop biosimilars with speed and quality, and we've proven these capabilities across multiple regulatory procedures across the globe.

At the same time, the commercial experience gained from our first-generation products has given us valuable insights into what it takes to succeed in an increasingly competitive biosimilar market. These learnings have become an important part of the compass for FYB4Growth. Our second-generation portfolio is therefore being built with an even stronger focus on market access, competitive differentiation, global diversification, and cost-efficient development and manufacturing. For every new project, we build price, access, competition, and cost into the center from the beginning. FYB206 is perhaps the strongest example of that evolution. With the FDA file acceptance announced in October, FYB206 has reached another major milestone in our ambition to develop a biosimilar to the world's largest biologic medicine, KEYTRUDA. While we are adjusting our economic expectation for our first-generation products, we are simultaneously creating the foundations for the next generation of Formycon.

That's the strategic perspective I would like you to take away from this slide. Let me now turn to what we have achieved since our half-year call in August. The clear highlight was, of course, the FDA file acceptance for FYB206 in October, together with our partners, Zydus Lifesciences. Under the applicable FDA review timeline, a regulatory decision could be expected in the third quarter of 2027. We have also initiated the regulatory procedure in Canada, another attractive market, and we intend to follow with additional submissions in further jurisdictions. This milestone was strongly enabled to remind us all by our streamlined clinical approach, relying on extensive analytical and functional comparability data together with pharmacokinetic evidence. The scientific principles behind this approach were published in the peer-reviewed journal, BioDrugs, in September.

Compared with the traditional phase III pathway, we avoided development expense in the high double-digit million EUR range and materially shortened the development timeline. This is FYB4Growth in action, not lowering scientific standards, but applying modern science smartly to generate robust evidence more efficiently. Let me take maybe here the opportunity to be precise about why FYB206 is different from FYB202. There are main three reasons. First, the market in the U.S. works differently. Pembrolizumab is predominantly administered in the medical benefit, so-called buy-and-bill channel. Its commercial access dynamics therefore differ from the pharmacy benefit market, where formulary access has been one of the major challenges for FYB202. In this channel, buy-and-bill channel, oncology biosimilars in the U.S. have reached majority shares within a few years, in some cases more than 80% of the total volume market for bevacizumab, trastuzumab, and rituximab, for instance. Second, timing.

With the FDA file acceptance in October, we are early in one of the largest markets for any biologic medicine. Third, we will be prepared when prices come down in this market. We are planning for that by establishing a very cost-competitive supply chain. Different does not mean risk-free, but there are multiple good reasons not to simply extrapolate FYB202 experience to FYB206. There is another development that perhaps received less attention than it deserved. We signed an agreement some weeks ago with Santo Biosimilar and Biocelys for a new biosimilar program, FYB286. I consider this a strategically important milestone for three reasons.

First, it adds an attractive niche-buster opportunity to our portfolio and strengthens our pipeline beyond our existing late-stage programs. Second, it demonstrates the continued commitment of our main shareholder to both biosimilars and Formycon. Third, the co-development approach with Biocelys and its state-of-the-art biologics manufacturing capabilities in South America adds another important element to our global manufacturing network. This is very much in line with the FYB4Growth. Our ambition is not only to build an attractive pipeline, we also want to build the development and manufacturing infrastructure that allows us to remain sustainably cost-competitive as the global biosimilar market evolves.

Our momentum doesn't stop here. We expect further important milestones during the fourth quarter, including the launch of FYB203 in the U.S., a FYB206 partnership for the LATAM region, as well as further additions to our portfolio. So you can expect continued news flow from Formycon over the coming weeks and months. With that, I conclude my part of the presentation and hand over to our CFO, Enno Spillner, who will take you through the financial results of the first nine months of 2026 and explain last week's accounting adjustments in more detail.

Enno Spillner
CFO, Formycon

Thank you, Stefan, and a good afternoon or good morning, respectively, also from my side. It is a pleasure to guide you through the nine-month 2026 numbers. Let me start with the nine-month revenue performance. Group revenues more than doubled to EUR 40 million from EUR 19.5 million in the first nine months of 2025. The main growth drivers were deferred revenue recognition from milestone payments related to our new FYB206 partnerships, which were signed late 2025 and early 2026, plus the one-off auto-injector milestone for FYB202. In addition, we recognized more than doubling royalty and commercialization revenues from the existing product portfolio, especially again from FYB202. A new revenue category comes from our supply management, still small, but a class we will continue to see going forward in the future.

In reverse, recharges for development work further decreased as anticipated due to little development work remaining with the mature products such as FYB201 and FYB203. The three approved and marketed biosimilars, 201, 202, and 203, including related services income, continue to make a significant portion or contribution to group revenues, accounting for approximately EUR 22.4 million, or about 56% of our current total. Together with our commercialization partners, we remain firmly focused on expanding the market presence and revenue potential of our existing portfolio of approved products, thereby supporting the financial foundation of our next phase of growth. Our product, FYB201, continues to be commercialized across various markets and to be relaunched in the U.S. after the hold in 2025. However, increasing competition and emerging therapeutic alternatives, particularly in the U.S., continue to weigh on revenue development. FYB202 significantly increased its revenue contribution to EUR 13.4 million.

This growth was primarily driven by the commercialization, supply management, and milestone revenues related to the Otulfi auto-injector. Despite progress in securing market access, the market environment remains very challenging, particularly in the U.S., due to intense price competition and complex reimbursement mechanisms. FYB203 generated revenues primarily from development recharges. As you may recall, FYB203 has been commercially available in Europe since mid-May of this year, 2026, and together with our partners, we are working to further expand commercialization activities and enter additional markets like, for instance, the U.S., ideally end of this year. FYB206, our biosimilar to KEYTRUDA, generated revenues of EUR 17.7 million, resulting mainly from deferred milestone recognition. FYB206 is therefore a new key revenue driver in the current financial year and is gaining further strategic importance as the regulatory approval process is going forward.

Alongside the current contribution from FYB206, our commercialized portfolio remains an important part of our revenue base. Maximizing its commercial potential continues to be a key operational priority as we work towards the next phase of portfolio growth. Looking at our cost of sales, cost of sales amounted to approximately EUR 47.9 million compared with EUR 37.3 million a year earlier. The increase is mainly associated to FYB206 performance obligations in context of our deferred milestone revenue recognition. Costs of the remaining portfolio are in context with the respective commercially related activities. A major block of almost EUR 16 million reflects the ongoing regular amortization relating to our FYB206 asset, which is neither an EBITDA nor a cash event. Our reported EBITDA improved to -EUR 8.9 million from -EUR 21.4 million in the comparable prior year period.

Adjusted EBITDA, which additionally reflects our share of the at-equity result from Bioeq AG, improved to -EUR 14.9 million from -EUR 21.7 million. These are very noticeable improvements year-on-year and confirm our growth ambition. However, these KPIs remain below our expectations so far because of the lower-than-anticipated market performance of FYB201 and FYB202 in particular. The significant data on other expenses as well as consolidated net result versus previous year are a consequence of the non-cash effective impairments of FYB201 and FYB202 assets versus corresponding effects from earn-out liabilities and deferred taxes. I will come back to this on the next slides during our presentation. Capitalized development expenditure for FYB206 and FYB208 was approximately EUR 16.2 million compared with EUR 31.9 million a year earlier.

This reduction primarily reflects the successful completion of the major FYB206 clinical work and the transition of some activities into costs associated with partner performance obligations. on November 5th, we announced that the updated commercial forecast from our partners, plus the overall market development, required us during our regular impairment testings to reassess the carrying values associated with FYB201 and FYB202. Both products face additional competitors, increasing price pressure, and therapeutic alternatives. For FYB202, formulary access in the U.S. remains an additional challenge. The revised forecast of each product reduced the expected future economic contribution from these products. That is the commercial reasoning behind our valuation updates. Let me now explain the balance sheet mechanism, starting with FYB201 on this page. For FYB201, the revised set expectations resulted in a EUR 107 million impairment of our investment in Bioeq AG.

At the same time, the related earn-out liabilities decreased as a counterbalancing effect significantly by EUR 68 million. This brings the net negative impact on our consolidated result to EUR 38 million. Important to notice, our EUR 46 million loan to Bioeq remains fully recoverable, and the adjustments do not affect our 2026 EBITDA or cash position. The revised outlook reflects the challenging market environment and lower expected commercial contributions in the subsequent years. We are reviewing the underlying cost structure and commercial assumptions closely with the objective of improving the earnings profile over time. However, we do not want to suggest that market challenges will disappear in the near term. Turning to FYB202, the underlying mechanism is very similar to FYB201.

The revised sales forecast, particularly for the U.S. and for the European markets, resulted in an impairment charge of EUR 131 million on the capitalized product rights, including the auto-injector. This is partially offset by EUR 30 million in deferred tax income and a EUR 19 million reduction in the contingent purchase price liability. The resulting net impact on our consolidated result is therefore minus EUR 82 million. As with FYB201, these are non-cash accounting adjustments that do not affect reported EBITDA or our 2026 liquidity. At the same time, we remain focused on expanding the commercial reach of FYB202 together with our partners. It's also very important to remember where these assets come from. Our first products were almost immediately out-licensed and financed by partners, above all, Athos, who carried the development and the financial risk at that point in time. In return, they participate in the upside.

As a reminder, we reacquired the economic rights of FYB201 and FYB202 from Athos in 2022, partially via contribution in kind as a transaction versus shares, and linked to future product revenues and respective earn-out obligations. This chart puts the adjustment into historical perspective for both products. Since the acquisition in 2022, the carrying value of our investment in Bioeq AG has gradually declined, reflecting the company's at-equity results and previous valuation adjustments. It does not show the counterbalancing earn-out effects that we also have, simply for simplicity on this slide. This carrying value of our investment in Bioeq declined from approximately EUR 135 million at year-end 2025 to approximately EUR 129 million before the impairment, reflecting our share of Bioeq's result for the first nine months.

The latest reassessment of approximately EUR 107 million then reduced the carrying value to approximately EUR 22 million at the end of September 2026. In previous periods, positive contributions from Bioeq underlying at-equity result partially offset negative valuation effects in our consolidated result. However, in the first nine months of 2026, both the underlying at-equity result and the impairment charge had a negative effect on consolidated earnings. This reflects the substantially revised long-term market expectations for FYB201, and nevertheless, the product remains commercialized, and we continue to work with our partners to realize its remaining market potential. Equal to what I have just explained for FYB201, the chart on the right illustrates how the carrying value of FYB202 has developed since the acquisition in 2022.

Following additions in the early development phase from capitalized development activities, the value has declined through both regular amortization and impairment adjustments from EUR 485 million at the end of 2023 to approximately EUR 165 million as of September 2026. Let me conclude on this with three important points. First, the combined net impact of FYB201 and FYB202 adjustments amounts to EUR 120 million in total, with no direct cash impact in 2026. At the same time, the revenue-linked earn-out liabilities decreased as a result of the lower sales expectations. Second, the size of these impairments also reflects the accounting history of FYB201 and FYB202. Both programs were reacquired in 2022 at an advanced stage of development, with their carrying NPV values reflecting the expected future commercial potential at that time.

As a result, the balance sheet values were significantly higher than those of internally developed programs, where only eligible late-stage development costs are normally capitalized. This explains why changes in revenue expectations have a particular pronounced impact on the carrying values of FYB201 and FYB202. Third, our next-generation programs, including FYB206, FYB208, and FYB286, are not affected. FYB206, in particular, was developed and financed by Formycon without revenue-linked acquisition liabilities. Here we have full commercial ownership and late-stage capitalization of development investments only. Let me turn to liquidity and the balance sheet. At September 30th, cash and cash equivalents amounted to approximately EUR 42.5 million, compared with EUR 68.8 million at the beginning of the year. Net cash used in investing activities was principally reflecting investment in our development programs, partially offset by a loan repayment from Bioeq AG. Financing cash flow was including earn-out settlements and bond interest payments.

Working capital amounted to approximately EUR 40.6 million at the end of September, compared with EUR 70 million as of December 31, 2025. The decline is primarily driven by the lower cash balance alongside changes in inventories, receivables, payables, and contract liabilities. Following the impairment adjustments and related offsetting effects, IFRS consolidated total assets stood at approximately EUR 467 million, mainly affected by the value adjustments and resulting net loss. Equity for the same reason totaled at approximately EUR 244 million, and the equity ratio remains stable at 52%. With a cash balance of EUR 42.5 million at the end of September, expected milestone payments from FYB206, and our continued focus on financial discipline, we believe we are appropriately positioned from a financial perspective. At the same time, our FYB4Growth strategy envisages further portfolio expansion. Any additional development projects beyond our current portfolio will require additional financing.

Like in the past, we continue evaluating suitable financing options, including capital-efficient partnering structures, to support these future growth opportunities. That said, no immediate financing measures is anticipated at this point. Finally, let me address our 2026 guidance. As announced already last week, our revenue guidance of EUR 60 million-EUR 70 million and our EBITDA guidance of EUR 0 million-EUR 10 million remains unchanged. For both metrics, we now expect to finish at the lower end of the respective ranges. Our year-on-year working capital guidance of EUR 20 million-EUR 30 million also remains unchanged.

We have revised, however, our adjusted EBITDA guidance to the range of minus EUR 15 million to minus EUR 5 million from the previous positive EUR 5 million-EUR 15 million. Again, this adjustment reflects the weaker expected result from our joint venture, Bioeq AG, which is included in the adjusted EBITDA, but not in our standard reported EBITDA. Our guidance incorporates the latest partner forecasts and updates and our current expectation for the fourth quarter. As Stefan said, our business is not linear. Given the nine-month position, the fourth quarter is expected to carry a significant part of the full-year contribution.

The lower end of our revenue range implies approximately EUR 20 million in fourth-quarter revenue, while reaching EBITDA break-even requires a contribution of around EUR 9 million in Q4. We expect this improvement to be driven primarily by FYB206-related deferred revenue recognition, improved FYB202 royalty performance in Q4, and first positive impact from our new FYB286 collaboration, while at the same time executing strict cost control across the full organization. The timing of these items is important, and our guidance reflects our current assessment of their expected recognition before year-end.

To summarize, the nine-month figures show clear year-on-year progress. The markets for our first-generation products have changed and remain challenging. We have reflected that in our valuation and in our adjusted EBITDA guidance. Our focus is now on disciplined execution, liquidity management, and directing investments towards the programs with the strongest future potential. With that, thank you very much for your attention, and Stefan, back to you.

Stefan Glombitza
CEO, Formycon

Yeah, thank you, Enno. Let me close the presentation part with three key takeaways, as you mostly summarized as well. First, the markets of FYB201 and FYB202 have changed, and we have said that so openly and adjusted our planning on our balance sheet, and we understand the disappointment. Acknowledging market realities is, of course, what allows us to make educated decisions and adjust our strategy. At the same time, we remain focused on extracting value from our commercialized products, which continue to support our business as we build the next generation of sustainable commercial success for Formycon. Second, the progress with FYB206 is real and strategically significant. We were the first company worldwide to announce FDA file acceptance for a biosimilar candidate to the world's best-selling biologic medicine using a science-led, more efficient development path.

We have strong regional commercialization partners, and we are preparing carefully for the regulatory and commercial steps ahead. The third FYB4Growth is becoming visible in the way we operate. More selective pipeline, modernized development processes and extended manufacturing network, and an emphasis on competitive manufacturing economics. FYB208, our dupilumab biosimilar candidate, for instance, and the additional opportunities we are evaluating are part of the next chapter. Thank you for your attention, and we will now open the call for your questions.

Operator

Ladies and gentlemen, we will now start the Q&A session. To ask a question, please press star nine and pound key on your telephone keypad. If you would like to revoke your question, press star three and pound key. You can also use the dial-in function in the webcast and raise your hand to ask a question. The first question comes from Simon Scholes at First Berlin Equity Research. Your line is open now.

Simon Scholes
Senior Analyst of Biotech and Resources, First Berlin Equity Research

Yes, good afternoon. Thanks for taking my questions. I have two. The first is on COGS. It looks as if you had a bump up in COGS in Q3. As you said, that is probably, I mean, that is related, it looks as if that is related to FYB206. So I was assuming that is also related to expense in connection with the BLA submission. So I was just wondering what COGS in connection specifically with FYB206, if you can tell me, if you can tell us what that might look like over the next few quarters. Then the second thing, my second question is on the marketing partnership for FYB206 in Europe. Can you give us an idea of when you might make an announcement in that regard?

Stefan Glombitza
CEO, Formycon

Yes. Thank you, Simon, for your good questions. The first one relates to COGS in Q3 related to 206 and FDA submission. Question to Enno. I mean, I could add to that as well if needed, but Enno is the most, yeah.

Enno Spillner
CFO, Formycon

No, absolutely right. Welcome, Simon, to the call. First of all, correct, the vast majority of our COGS, as already also shown on our slides, is the associated performance obligation to fulfill the criteria for our milestones. You recognize that, as I mentioned, we have an increased revenue part from deferred milestones coming through 206. Of course, to achieve these milestones, we have associated efforts, which then will also continue in 2027 until we hopefully achieve approval in Q3 2027. So during that time, we will, A, recognize the deferred milestones, and B, also the associated COGS. You can basically balance these two amounts, so there will not be a huge margin on the revenues, but COGS are very close to the respective revenues. This is the major COGS driver which will go forward until Q3 of next year from that perspective.

Simon Scholes
Senior Analyst of Biotech and Resources, First Berlin Equity Research

Okay.

Stefan Glombitza
CEO, Formycon

Thanks, Enno. Handover to Nicola, as she and her team are heavily involved in negotiations with the interested partners for Europe. Nicola, can you give us the status update there?

Nicola Mikulcik
Chief Business Officer, Formycon

Thank you, Simon, for your question. Yeah, we are at the moment in very active and, especially for the LATAM region, very advanced discussions. I think, especially on LATAM, that is going really to a closing very soon. Regarding Europe, you know probably that there is a bit more time because the patent expires later in Europe. Still, since our announcement on the U.S. acceptance to file, we see, of course, a lot of also interest from European companies, very different types of companies. We are, as we discuss with those companies, defining our strategy, what's really the best way of covering a territory like Europe, which is very volatile and very different in its nature country by country. Therefore, we are, yeah, having different scenarios and will also, I expect, deals next year to be closed.

Simon Scholes
Senior Analyst of Biotech and Resources, First Berlin Equity Research

Okay. Thanks very much. That is very helpful.

Stefan Glombitza
CEO, Formycon

Thanks, Simon.

Operator

Yes, I will repeat. To ask a question, you can press star nine and pound key, or you could just use the dial-in function in the webcast and raise your hand. The next question is from Alexander Zienkowicz at AlsterResearch. Your line is open now.

Alexander Zienkowicz
Senior Equity Research Analyst, AlsterResearch

Good afternoon. Thanks for taking my question. Could you clarify whether the partnership in LATAM is already included in your 2026 guidance? Following up on that, could you clarify what the remaining milestone opportunities are for FYB206 in 2027 besides partnership in Europe? Thanks.

Stefan Glombitza
CEO, Formycon

Yeah, thanks, Alexander. Maybe I can even take those two without referring to my colleagues. Partnership LATAM is clearly included in the guidance for this year. No further partnership more. This will be part of the revenue incomes for 2027. The milestones we expect, and which are already agreed in contracts, is of course for different approvals on the territories. Those will be added, and those are as soon as we get the approvals in the respective countries, we will be applicable for those milestone payments. And of course, further partnerships in other territories and maybe double partnerships, semi-exclusive, all that kind of additional partnerships will add to the 2027 revenues. Does that answer your questions?

Alexander Zienkowicz
Senior Equity Research Analyst, AlsterResearch

Yes, very helpful. Thanks. Maybe on FYB208, do you expect any partnerships next year for FYB208, or is it too early yet?

Nicola Mikulcik
Chief Business Officer, Formycon

We are working on that as well. Also, we are also considering some co-development partnerships, but we have not yet decided on the best strategy. Yeah, this is early stage, and we would like to keep it open for now, what exactly the strategy will be. I mean, this product is still a bit further out, and therefore, it depends also, of course, on the activity on the market. And we see in general more and more, of course, companies who know that they will need biosimilars in their portfolio globally, because of the quite condensed generic markets, and therefore, there is definitely a lot of interest. But what is the right strategy for FYB208, I think we will just define going forward. So I cannot precisely answer that question today.

Stefan Glombitza
CEO, Formycon

Maybe to add operationally, we are going full steam ahead. So independent of partnering activities, we also achieved already streamlined okay for the clinical program and strategy, and we are going at commercial scale already in manufacturing. So those are our activities that are independently proceeding, and then Nicola and her team will find the best moment to partner.

Alexander Zienkowicz
Senior Equity Research Analyst, AlsterResearch

Okay, understood. Thanks.

Stefan Glombitza
CEO, Formycon

Thanks, Alex.

Operator

Moment, there seem to be no further questions. With that, I will hand you over to our speaker for closing remarks.

Stefan Glombitza
CEO, Formycon

Yeah, so finally, I would like to thank the operator, our investor relations team, my board colleagues, and especially everyone who joined today's earnings call. We know where the market has challenged us, and we have taken the learnings on board, and we are acting on them. With FYB4Growth, maturing pipeline, and the progress we are making with such programs such as FYB206, we believe we are building a stronger and more competitive Formycon even in the future. With a clear strategy, a strong execution, and I can witness also a highly motivated team, our ambition remains unchanged. To create sustainable long-term value for our shareholders while making high-quality biologic medicines more accessible to patients around the world. So thank you for your trust, your time, and your continued support.